{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,2]],"date-time":"2026-02-02T06:53:45Z","timestamp":1770015225230,"version":"3.49.0"},"reference-count":30,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2016,8,1]],"date-time":"2016-08-01T00:00:00Z","timestamp":1470009600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Antiviral Research"],"published-print":{"date-parts":[[2016,8]]},"DOI":"10.1016\/j.antiviral.2016.06.008","type":"journal-article","created":{"date-parts":[[2016,6,24]],"date-time":"2016-06-24T06:22:20Z","timestamp":1466749340000},"page":"204-209","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":16,"special_numbering":"C","title":["Impact of glycoprotein B genotype and naturally occurring ORF UL56 polymorphisms upon susceptibility of clinical human cytomegalovirus isolates to letermovir"],"prefix":"10.1016","volume":"132","author":[{"given":"Peter","family":"Lischka","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Douglas","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Daniel","family":"Holder","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Holger","family":"Zimmermann","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.antiviral.2016.06.008_bib1","doi-asserted-by":"crossref","first-page":"1673","DOI":"10.1172\/JCI45449","article-title":"Cytomegalovirus: pathogen, paradigm, and puzzle","volume":"121","author":"Boeckh","year":"2011","journal-title":"J.\u00a0Clin. Investig."},{"key":"10.1016\/j.antiviral.2016.06.008_bib2","doi-asserted-by":"crossref","first-page":"643","DOI":"10.1177\/135965350801300504","article-title":"Putative functional domains of human cytomegalovirus pUL56 involved in dimerization and benzimidazole D-ribonucleoside activity","volume":"13","author":"Champier","year":"2008","journal-title":"Antivir. Ther."},{"key":"10.1016\/j.antiviral.2016.06.008_bib3","doi-asserted-by":"crossref","first-page":"1781","DOI":"10.1056\/NEJMoa1309533","article-title":"Letermovir for cytomegalovirus prophylaxis in hematopoietic-cell transplantation","volume":"370","author":"Chemaly","year":"2014","journal-title":"N.\u00a0Engl. J. Med."},{"key":"10.1016\/j.antiviral.2016.06.008_bib4","doi-asserted-by":"crossref","first-page":"6588","DOI":"10.1128\/AAC.01623-15","article-title":"Rapid in\u00a0vitro evolution of human cytomegalovirus UL56 mutations that confer letermovir resistance","volume":"59","author":"Chou","year":"2015","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.antiviral.2016.06.008_bib5","doi-asserted-by":"crossref","first-page":"1229","DOI":"10.1093\/infdis\/163.6.1229","article-title":"Analysis of interstrain variation in cytomegalovirus glycoprotein B sequences encoding neutralization-related epitopes","volume":"163","author":"Chou","year":"1991","journal-title":"J.\u00a0Infect. Dis."},{"key":"10.1016\/j.antiviral.2016.06.008_bib6","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1086\/421496","article-title":"Mixed cytomegalovirus glycoprotein B genotypes in immunocompromised patients","volume":"39","author":"Coaquette","year":"2004","journal-title":"Clin. Infect. Dis."},{"key":"10.1016\/j.antiviral.2016.06.008_bib7","doi-asserted-by":"crossref","first-page":"310","DOI":"10.1186\/1471-2334-13-310","article-title":"Cytomegalovirus (CMV) genotype in allogeneic hematopoietic stem cell transplantation","volume":"13","author":"Dieamant","year":"2013","journal-title":"BMC Infect. Dis."},{"key":"10.1016\/j.antiviral.2016.06.008_bib8","doi-asserted-by":"crossref","first-page":"114","DOI":"10.1086\/341071","article-title":"Cytomegalovirus glycoprotein B groups in human immunodeficiency virus-infected patients with incident retinitis","volume":"186","author":"Drew","year":"2002","journal-title":"J.\u00a0Infect. Dis."},{"key":"10.1016\/j.antiviral.2016.06.008_bib9","doi-asserted-by":"crossref","first-page":"610","DOI":"10.1128\/AAC.01794-13","article-title":"Geno- and phenotypic characterization of human cytomegalovirus mutants selected in\u00a0vitro after letermovir (AIC246) exposure","volume":"58","author":"Goldner","year":"2014","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.antiviral.2016.06.008_bib10","doi-asserted-by":"crossref","first-page":"10884","DOI":"10.1128\/JVI.05265-11","article-title":"The novel anticytomegalovirus compound AIC246 (Letermovir) inhibits human cytomegalovirus replication through a specific antiviral mechanism that involves the viral terminase","volume":"85","author":"Goldner","year":"2011","journal-title":"J.\u00a0Virol."},{"key":"10.1016\/j.antiviral.2016.06.008_bib11","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1016\/j.antiviral.2015.01.006","article-title":"Phenotypic characterization of two naturally occurring human Cytomegalovirus sequence polymorphisms located in a distinct region of ORF UL56 known to be involved in in\u00a0vitro resistance to letermovir","volume":"116","author":"Goldner","year":"2015","journal-title":"Antivir. Res."},{"key":"10.1016\/j.antiviral.2016.06.008_bib12","doi-asserted-by":"crossref","first-page":"605","DOI":"10.1097\/QCO.0b013e32834cfb58","article-title":"The biology of cytomegalovirus drug resistance","volume":"24","author":"Hakki","year":"2011","journal-title":"Curr. Opin. Infect. Dis."},{"key":"10.1016\/j.antiviral.2016.06.008_bib13","doi-asserted-by":"crossref","first-page":"581","DOI":"10.1086\/377002","article-title":"Cytomegalovirus (CMV) glycoprotein B genotypes and response to antiviral therapy, in solid-organ-transplant recipients with CMV disease","volume":"188","author":"Humar","year":"2003","journal-title":"J.\u00a0Infect. Dis."},{"key":"10.1016\/j.antiviral.2016.06.008_bib14","doi-asserted-by":"crossref","first-page":"3891","DOI":"10.1128\/JVI.01251-08","article-title":"Human cytomegalovirus glycoprotein B is required for virus entry and cell-to-cell spread but not for virion attachment, assembly, or egress","volume":"83","author":"Isaacson","year":"2009","journal-title":"J.\u00a0Virol."},{"key":"10.1016\/j.antiviral.2016.06.008_bib15","doi-asserted-by":"crossref","first-page":"1079","DOI":"10.1111\/j.1600-6143.2011.03530.x","article-title":"First report of successful treatment of multidrug-resistant cytomegalovirus disease with the novel anti-CMV compound AIC246","volume":"11","author":"Kaul","year":"2011","journal-title":"Am. J. Transpl."},{"issue":"Suppl.\u00a03","key":"10.1016\/j.antiviral.2016.06.008_bib16","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1111\/ajt.12006","article-title":"CMV: prevention, diagnosis and therapy","volume":"13","author":"Kotton","year":"2013","journal-title":"Am. J. Transpl."},{"key":"10.1016\/j.antiviral.2016.06.008_bib17","doi-asserted-by":"crossref","first-page":"1290","DOI":"10.1128\/AAC.01596-09","article-title":"In\u00a0vitro and in\u00a0vivo activities of the novel anticytomegalovirus compound AIC246","volume":"54","author":"Lischka","year":"2010","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.antiviral.2016.06.008_bib18","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1093\/infdis\/jiv352","article-title":"Characterization of cytomegalovirus breakthrough events in a Phase 2 prophylaxis trial of letermovir (AIC246, MK 8228)","volume":"213","author":"Lischka","year":"2016","journal-title":"J.\u00a0Infect. Dis."},{"key":"10.1016\/j.antiviral.2016.06.008_bib19","doi-asserted-by":"crossref","first-page":"541","DOI":"10.1016\/j.coph.2008.07.002","article-title":"Antiviral strategies to combat cytomegalovirus infections in transplant recipients","volume":"8","author":"Lischka","year":"2008","journal-title":"Curr. Opin. Pharmacol."},{"key":"10.1016\/j.antiviral.2016.06.008_bib20","doi-asserted-by":"crossref","first-page":"1160","DOI":"10.1086\/605633","article-title":"Impact of genetic polymorphisms in cytomegalovirus glycoprotein B on outcomes in solid-organ transplant recipients with cytomegalovirus disease","volume":"49","author":"Manuel","year":"2009","journal-title":"Clin. Infect. Dis."},{"key":"10.1016\/j.antiviral.2016.06.008_bib21","doi-asserted-by":"crossref","first-page":"1135","DOI":"10.1128\/AAC.05908-11","article-title":"In\u00a0vitro evaluation of the activities of the novel anticytomegalovirus compound AIC246 (letermovir) against herpesviruses and other human pathogenic viruses","volume":"56","author":"Marschall","year":"2012","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.antiviral.2016.06.008_bib22","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1016\/j.intimp.2008.08.020","article-title":"Clinical correlations of human cytomegalovirus strains and viral load in kidney transplant recipients","volume":"9","author":"Nogueira","year":"2009","journal-title":"Int. Immunopharmacol."},{"key":"10.1016\/j.antiviral.2016.06.008_bib23","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1016\/j.antiviral.2014.08.014","article-title":"Human cytomegalovirus (CMV) susceptibility to currently approved antiviral drugs does not impact on CMV terminase complex polymorphism","volume":"111","author":"Pilorge","year":"2014","journal-title":"Antivir. Res."},{"key":"10.1016\/j.antiviral.2016.06.008_bib24","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1016\/j.jcv.2006.03.004","article-title":"Cytomegalovirus and Epstein-Barr virus subtypes\u2013the search for clinical significance","volume":"36","author":"Puchhammer-Stockl","year":"2006","journal-title":"J.\u00a0Clin. Virol."},{"key":"10.1016\/j.antiviral.2016.06.008_bib25","series-title":"Human Cytomegalovirus","article-title":"Pathogenesis in transplant recipients","author":"Sampathkumar","year":"2007"},{"key":"10.1016\/j.antiviral.2016.06.008_bib26","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1016\/S1386-6532(01)00238-4","article-title":"Cytomegalovirus glycoprotein B genotype does not correlate with outcomes in liver transplant patients","volume":"24","author":"Sarcinella","year":"2002","journal-title":"J.\u00a0Clin. Virol."},{"key":"10.1016\/j.antiviral.2016.06.008_bib27","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1111\/tri.12225","article-title":"Preemptive treatment of Cytomegalovirus infection in kidney transplant recipients with letermovir: results of a Phase 2a study. Transplant international","volume":"27","author":"Stoelben","year":"2014","journal-title":"Official J. Eur. Soc. Organ Transplant."},{"key":"10.1016\/j.antiviral.2016.06.008_bib28","doi-asserted-by":"crossref","first-page":"2097","DOI":"10.1182\/blood.V90.5.2097","article-title":"Association of specific cytomegalovirus genotypes with death from myelosuppression after marrow transplantation","volume":"90","author":"Torok-Storb","year":"1997","journal-title":"Blood"},{"key":"10.1016\/j.antiviral.2016.06.008_bib29","doi-asserted-by":"crossref","first-page":"647","DOI":"10.1016\/j.bbmt.2009.12.001","article-title":"Cytomegalovirus glycoprotein B genotype in hematopoietic stem cell transplant patients from China","volume":"16","author":"Wu","year":"2010","journal-title":"Biol. Blood Marrow Transpl."},{"key":"10.1016\/j.antiviral.2016.06.008_bib30","series-title":"Practical Data Analysis for Designed Experiments","author":"Yandell","year":"1997"}],"container-title":["Antiviral Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S016635421630153X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S016635421630153X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2022,7,2]],"date-time":"2022-07-02T03:52:41Z","timestamp":1656733961000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S016635421630153X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,8]]},"references-count":30,"alternative-id":["S016635421630153X"],"URL":"https:\/\/doi.org\/10.1016\/j.antiviral.2016.06.008","relation":{},"ISSN":["0166-3542"],"issn-type":[{"value":"0166-3542","type":"print"}],"subject":[],"published":{"date-parts":[[2016,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Impact of glycoprotein B genotype and naturally occurring ORF UL56 polymorphisms upon susceptibility of clinical human cytomegalovirus isolates to letermovir","name":"articletitle","label":"Article Title"},{"value":"Antiviral Research","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.antiviral.2016.06.008","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2016 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}]}}